BB Biotech AG (CHIX:BIONZ) Loans Receivable: CHF Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:BIONZ BB Biotech AG CHIX:BIONZ
15 GF Score
Price CHF51.80
! 3 Warning Signs
View Full Analysis

What is BB Biotech AG Loans Receivable?

BB Biotech AG CHIX:BIONZ 15 Loans Receivable is CHF Mil as of Jun. 2026. GuruFocus rates CHIX:BIONZ with a GF Score™ of 15/100. The stock has 3 warning signs investors should review.

BB Biotech AG's Loans Receivable for the quarter that ended in Jun. 2026 was CHF Mil.

BB Biotech AG Loans Receivable Historical Data

* Premium members only.

The historical data trend for BB Biotech AG's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BB Biotech AG Loans Receivable Chart

BB Biotech AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BB Biotech AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
CHIX:BIONZ
15GF Score
BB Biotech AG CHIX:BIONZ
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BB Biotech AG Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of CHF Mil mean?
BB Biotech AG (CHIX:BIONZ) has a Loans Receivable of CHF Mil as of Jun. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on BB Biotech AG and its competitors.
Is BB Biotech AG's Loans Receivable too high?
BB Biotech AG's current Loans Receivable is CHF Mil. Overall, BB Biotech AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does BB Biotech AG's Loans Receivable compare to VRTX and REGN?
BB Biotech AG's Loans Receivable of CHF Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on BB Biotech AG and its competitors. BB Biotech AG's current Loans Receivable is CHF Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BB Biotech AG stock overvalued right now?
BB Biotech AG (CHIX:BIONZ) has a current Loans Receivable of CHF Mil. The current Loans Receivable is CHF Mil. BB Biotech AG's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For BB Biotech AG (CHIX:BIONZ), the current Loans Receivable is CHF Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BB Biotech AG Business Description

Other Exchanges BION:Switzerland
Address Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. Geographically company operates in the USA, Netherlands, Singapore, Great Britain, Canada, Switzerland, Curacao, and British Virgin Island.
15GF Score

Get the complete analysis for CHIX:BIONZ

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF51.80
Price